BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says

MT Newswires Live12-11

BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib, RBC Capital said in a Tuesday note.

The brokerage noted that new BRUIN-314 data show pirtobrutinib achieving a strong 93.4% 24-month PFS, while Brukinsa's COVID adjusted 6 year PFS of 74-77% annualizes to a comparable rate, indicating similar long-term efficacy.

According to the report, Brukinsa and pirtobrutinib may ultimately show similar performance, with physicians yet to identify a clear leader. Any competitive impact is likely to emerge gradually, given the long-term use of CLL therapies.

RBC highlighted that Brukinsa's superior drug profile and safety, along with its leading position in CLL/SLL, should drive ongoing growth, with US adoption already ahead of competitors.

Analysts forecast that Brukinsa could achieve peak sales of around $6.8 billion by 2030, reinforcing their view that BeOne's stock remains undervalued.

The firm maintained its outperform rating on the stock with a price target of $408.

Price: 318.93, Change: +0.24, Percent Change: +0.07

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590444539?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-11 00:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590444539","market":"sh","top_or_hot":-1,"title":"BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says","media":"MT Newswires Live","content":"<html><body><p> BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib, RBC Capital said in a Tuesday note.</p><p>The brokerage noted that new BRUIN-314 data show pirtobrutinib achieving a strong 93.4% 24-month PFS, while Brukinsa's COVID adjusted 6 year PFS of 74-77% annualizes to a comparable rate, indicating similar long-term efficacy.</p><p>According to the report, Brukinsa and pirtobrutinib may ultimately show similar performance, with physicians yet to identify a clear leader. Any competitive impact is likely to emerge gradually, given the long-term use of CLL therapies.</p><p>RBC highlighted that Brukinsa's superior drug profile and safety, along with its leading position in CLL/SLL, should drive ongoing growth, with US adoption already ahead of competitors.</p><p>Analysts forecast that Brukinsa could achieve peak sales of around $6.8 billion by 2030, reinforcing their view that BeOne's stock remains undervalued.</p><p>The firm maintained its outperform rating on the stock with a price target of $408.</p><p>Price: 318.93, Change: +0.24, Percent Change: +0.07</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines' Brukinsa Poised for Growth Through 2026 Despite Rising BTK Competition, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-11 00:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib, RBC Capital said in a Tuesday note.</p><p>The brokerage noted that new BRUIN-314 data show pirtobrutinib achieving a strong 93.4% 24-month PFS, while Brukinsa's COVID adjusted 6 year PFS of 74-77% annualizes to a comparable rate, indicating similar long-term efficacy.</p><p>According to the report, Brukinsa and pirtobrutinib may ultimately show similar performance, with physicians yet to identify a clear leader. Any competitive impact is likely to emerge gradually, given the long-term use of CLL therapies.</p><p>RBC highlighted that Brukinsa's superior drug profile and safety, along with its leading position in CLL/SLL, should drive ongoing growth, with US adoption already ahead of competitors.</p><p>Analysts forecast that Brukinsa could achieve peak sales of around $6.8 billion by 2030, reinforcing their view that BeOne's stock remains undervalued.</p><p>The firm maintained its outperform rating on the stock with a price target of $408.</p><p>Price: 318.93, Change: +0.24, Percent Change: +0.07</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590444539","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590444539","pubTimestamp":1765384283,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib,","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ONC":"百济神州","MDCO":"麦迪逊医药","BK4526":"热门中概股","BK4585":"ETF&股票定投概念"},"translate_title":"RBC表示，尽管BTK竞争日益激烈，BeOne Medicines的Brukinsa仍有望在2026年实现增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONC":1,"MDCO":1.5},"content_text":"BeOne Medicines' (ONC) Brukinsa continues to hold a strong competitive position in the chronic lymphocytic leukemia treatment market, even as new data emerges on competing BTK inhibitor pirtobrutinib, RBC Capital said in a Tuesday note.The brokerage noted that new BRUIN-314 data show pirtobrutinib achieving a strong 93.4% 24-month PFS, while Brukinsa's COVID adjusted 6 year PFS of 74-77% annualizes to a comparable rate, indicating similar long-term efficacy.According to the report, Brukinsa and pirtobrutinib may ultimately show similar performance, with physicians yet to identify a clear leader. Any competitive impact is likely to emerge gradually, given the long-term use of CLL therapies.RBC highlighted that Brukinsa's superior drug profile and safety, along with its leading position in CLL/SLL, should drive ongoing growth, with US adoption already ahead of competitors.Analysts forecast that Brukinsa could achieve peak sales of around $6.8 billion by 2030, reinforcing their view that BeOne's stock remains undervalued.The firm maintained its outperform rating on the stock with a price target of $408.Price: 318.93, Change: +0.24, Percent Change: +0.07","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590444539","isCrawlerRequest":true}